Thomas Mindt (LBI Applied Diagnostics): Development of Radiometal-Based Peptides and Proteins for Tumour Targeting
Christoph Denk (TU Wien und AIT): Bioorthogonal Ligations in Radiopharmaceutical Sciences
14:00-14:30: Begrüßung aller Teilnehmer (Oliver Langer, Wolfgang Wadsak) und kurze Vorstellrunde aller Teilnehmer
14:30-15:00: Kurzvortrag Thomas Mindt (LBI Applied Diagnostics): Development of Radiometal-Based Peptides and Proteins for Tumour Targeting
15:00-15:30: Kurzvortrag Christoph Denk (TU Wien und AIT): Bioorthogonal Ligations in Radiopharmaceutical Sciences
15:30-16:00: Diskussion möglicher Kooperationen (alle Teilnehmer)
Ab 16:00: Brötchen und Getränke
Development of Radiometal-Based Peptides and Proteins for Tumour Targeting
Application of metallic radionuclides in the development of tumour-targeting radiopharmaceuticals has the big advantage that it allows for exchanging the metal to obtain either diagnostic probes for imaging or agents for radioendotherapy (theranostic approach). The design and development of a radiometal-based tracer requires the optimization of each individual component of the conjugate (e.g., chelator, spacer, and vector) in order to adjust its chemical and biological properties. Different research projects of Prof. Mindt’s laboratories will be presented to illustrate the importance of such efforts in the development of radiolabelled peptides and proteins for applications in nuclear oncology.
Thomas Mindt obtained a chemical engineering degree from the University of Applied Sciences (Switzerland) and Ph.D. in organic chemistry from Brown University (USA). Upon return to Europe, he worked as a senior assistant in Radiopharmaceutical Sciences at the ETH in Zurich (Switzerland). In 2009, he accepted a call of the University of Basel (Switzerland) as an Assistant Professor in Radiopharmaceutical Chemistry. In 2016, he moved to Vienna as a co-founder of the new Ludwig Boltzmann Institute Applied Diagnostics.
Prof. Mindt’s research focuses on the interface of medicine and chemistry, in particular on the development of novel diagnostic (imaging) probes and therapeutics for applications nuclear oncology. He is interested in applications of metallic radionuclides in a theranostic approach, e.g., by developing novel synthetic chemistry for the radiolabelling of biologically active molecules.
Thomas Mindt is engaged internationally in the field of radiopharmaceutical sciences as a member of the Radiopharmacy and Scientific Program Committees of the European Association of Nuclear Medicine and as a reviewer for different societies and scientific journals. He has authored and co-authored more than 70 publications and patents.
Bioorthogonal Ligations in Radiopharmaceutical Sciences
Highly selective and fast biorthogonal ligations render biological systems into reaction vessels: Covalent linkages are formed in living systems with the aid of small molecule reactants. Those reactions allow manifold applications in radiomarmaceutical science and nuclear medicine. Long circulating agents (nanomedicines) can be visualized using short-lived PET nuclides, and off-target dose in radioimmunotherapy can be significantly lowered using these pre-targeting modes. Ligation rates, biodistribution, metabolic stability as well as membrane permeability of employed radiolabeled agents require optimization, to path the way for successful in vivo application. Within this talk our progress in the field of bioorthogonal chemistry and its application to radiochemistry and nuclear medicine will be presented.
Christoph Denk got involved in radiochemistry in 2008 as operator in the production of radiopharmaceuticals. In 2013 he obtained his MSc degree in synthetic chemistry from Vienna University of Technology for his thesis “Bioorthogonal Ligations in PET Imaging”. He obtained his Ph.D. from Prof. Johannes Fröhlich in 2016 following further optimization of biorthogonal agents for diagnostic and therapeutic applications.
As postdoctoral fellow his main research interests are the development of 18F-probes for intracellular click chemistry, as well as novel radiolabeling techniques. Christoph Denk has ongoing scientific collaborations with international research institutions including the European Institute of Molecular Imaging (Münster, Germany), Rigshospitalet (København, Denmark), Sahlgrenska University Hospital (Göteborg, Sweden) and the Austrian Institute of Technology. He is a member of the World of Molecular Imaging Society, and his work was published in peer-reviewed journals.